Business Description
Genor Biopharma Holdings Ltd
ISIN : KYG3871A1004
Share Class Description:
FRA:67N0: Ordinary SharesTotal Employee Number:
17Compare
Compare
Traded in other countries / regions
67N0.Germany IPO Date
2020-10-13Description
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1354.91 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -0.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 73.9 | |||||
3-Year EPS without NRI Growth Rate | 69.5 | |||||
3-Year FCF Growth Rate | 45.3 | |||||
3-Year Book Growth Rate | -24.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.62 | |||||
9-Day RSI | 40.97 | |||||
14-Day RSI | 42.83 | |||||
3-1 Month Momentum % | -8.33 | |||||
6-1 Month Momentum % | 48.41 | |||||
12-1 Month Momentum % | 96.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.93 | |||||
Quick Ratio | 4.93 | |||||
Cash Ratio | 4.8 | |||||
Days Inventory | 2010.31 | |||||
Days Payable | 45191.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.9 | |||||
Shareholder Yield % | 0.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.55 | |||||
Operating Margin % | 17.74 | |||||
Net Margin % | 15.01 | |||||
EBITDA Margin % | 22.13 | |||||
FCF Margin % | -3.79 | |||||
OCF Margin % | -3.34 | |||||
ROE % | 3.12 | |||||
ROA % | 2.66 | |||||
ROIC % | 9.81 | |||||
3-Year ROIIC % | -244.06 | |||||
ROC (Joel Greenblatt) % | 288.9 | |||||
ROCE % | 4.52 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 37.33 | |||||
PE Ratio without NRI | 24 | |||||
PEG Ratio | 0.48 | |||||
PS Ratio | 6 | |||||
PB Ratio | 1.32 | |||||
Price-to-Tangible-Book | 1.53 | |||||
EV-to-EBIT | 9.41 | |||||
EV-to-EBITDA | 9.41 | |||||
EV-to-Revenue | 2.08 | |||||
EV-to-FCF | -54.96 | |||||
Price-to-Graham-Number | 1.29 | |||||
| Price-to-Net-Current-Asset-Value | 1.77 | |||||
| Price-to-Net-Cash | 1.87 | |||||
Earnings Yield (Greenblatt) % | 10.63 | |||||
FCF Yield % | -0.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genor Biopharma Holdings Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 29.046 | ||
| EPS (TTM) (€) | 0.009 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 68.85 | ||
| 14-Day RSI | 42.83 | ||
| 14-Day ATR (€) | 0.009538 | ||
| 20-Day SMA (€) | 0.3622 | ||
| 12-1 Month Momentum % | 96.84 | ||
| 52-Week Range (€) | 0.185 - 0.57 | ||
| Shares Outstanding (Mil) | 524.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genor Biopharma Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genor Biopharma Holdings Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genor Biopharma Holdings Ltd Frequently Asked Questions
What is Genor Biopharma Holdings Ltd(FRA:67N0)'s stock price today?
The current price of FRA:67N0 is €0.34. The 52 week high of FRA:67N0 is €0.57 and 52 week low is €0.19.
When is next earnings date of Genor Biopharma Holdings Ltd(FRA:67N0)?
The next earnings date of Genor Biopharma Holdings Ltd(FRA:67N0) is .
Does Genor Biopharma Holdings Ltd(FRA:67N0) pay dividends? If so, how much?
Genor Biopharma Holdings Ltd(FRA:67N0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Genor Biopharma Holdings Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers